DFTX7:00 AMDefinium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conferencedefiniumtx.com
DFTX7:00 AMDefinium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive DisorderTrial Start • Phase 3Trial initiation Tue, May 12, 2026, 7:00 AM EDTGdefiniumtx.com
DFTX4:01 PMDefinium Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsEnrollment • Phase 3definiumtx.com
DFTX4:01 PMDefinium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026definiumtx.com
DFTX4:15 PMDefinium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst DayEnrollment • Phase 3definiumtx.com
DFTX7:38 PMDefinium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatmentsdefiniumtx.com
DFTX7:00 AMDefinium Therapeutics to Participate at Upcoming Investor Conferences and Eventsdefiniumtx.com
DFTX7:00 AMNew Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United Statesdefiniumtx.com
DFTX7:00 AMDefinium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026definiumtx.com